media – Page 571 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Sanofi to acquire Bioverativ for $11.6 billion

Sanofi SA (SAN.FR) said Monday that it will acquire all outstanding shares in Bioverativ Inc. BIVV, -0.61% for $11.6 billion to expand its presence in specialty care and strengthening leadership in rare diseases.
- Source: Marketwatch
- 481
- January 24, 2018
Market Views rare diseases
The Effects Of Air Pollution On Human Health

Although it isn’t talked about often, older adults in the United States are turning to drugs and alcohol at an alarming rate. Studies have found that a large population of older Americans are suffering from substance use disorders, and the number is only expected to rise. According to research, the number of Americans aged 50 and older struggling with addiction is expected to nearly double in the coming years, going from 2.8 million to 5.7 million by 2020.
- Source: msn
- 1,044
- January 24, 2018
air pollution asthma cardiovascular pneumonia
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C– a systematic review and meta-analysis

Direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection might pose a risk for hepatitis B virus (HBV) reactivation in patients coinfected with chronic or resolved HBV infection. The need for HBV antiviral prophylaxis during DAA treatment remains controversial. We aimed to analyse the absolute risk of HBV reactivation in patients with active or resolved HBV infection treated with DAAs for HCV infection.
- Source: Thelancet
- 505
- January 24, 2018
DAA HBV HCV Researches
Can digital tools really change patient behavior?

Using the virtual reality (VR) platform, doctors can show patients, in an immersive, highly detailed way, what will happen to their bodies if they take their medication, stop smoking, and eat better — and what will happen if they don't.
- Source: MM&M
- 795
- January 24, 2018
digital health medical device Virtual Reality wearables
‘Explosive evolution’ of techniques to restore blood flow to the brain

Recent decades have seen an "explosive evolution" of techniques to restore blood flow to areas of the brain endangered by stroke or clogged arteries, according to a report by Loyola Medicine neurologists and neurosurgeons.
- Source: Science Daily
- 676
- January 24, 2018
brain medical device Researches stroke surgery
Leaf Healthcare touts reduced pressure injuries in Leaf wearable sensor study

Patient monitoring system developer Leaf Healthcare today released results from a study exploring the ability of its Leaf wearable patient sensor to prevent pressure injuries on acutely ill adults, touting that patients were 73% less likely to develop such injuries when monitored with the device.
- Source: Mass Device
- 612
- January 24, 2018
medical device Researches wearables
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
- Source: Sandoz
- 596
- January 23, 2018
biosimilars immunology Market Views oncology
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 562
- January 23, 2018
Bavencio cancer inhibitor Market Views
Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...
- Source: Pharmatimes
- 567
- January 23, 2018
Avastin Mvasi New Approvals Roche
GSK, Pfizer lead in new global Twitter pharma influencer ranking

Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health. The U.K.-based healthcare marketing agency evaluated 22 pharma companies on authority, reach, activity, engagement and influence to rate the most and least adept when it comes to Twitter.
- Source: fiercepharma
- 627
- January 23, 2018
global pharma influencers GSK Pfizer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.